Combination treatment for advanced lung cancer after first immunotherapy
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new pill (golidocitinib) combined with an immunotherapy drug for people with advanced non-small cell lung cancer that has grown despite previous treatment. It may offer a new option for those who have already tried standard treatments.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older.
- You have advanced non-small cell lung cancer that has spread or come back, and you can't have surgery or radiation with curative intent.
- You have already been treated with an immunotherapy drug (like nivolumab or pembrolizumab) before, with or without chemotherapy, and your cancer stayed stable or improved for at least 6 weeks.
- You are not eligible for or refuse standard chemotherapy.
- You have at least one tumor that can be measured on scans.
- Your cancer does not have certain genetic changes (like EGFR or ALK) that have specific targeted treatments.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of golidocitinib (a targeted pill) and a PD-1 inhibitor (a type of immunotherapy) as a maintenance treatment after initial chemotherapy. It may help keep your lung cancer from growing longer.
This trial tests a combination of two drugs for people with advanced non-small cell lung cancer. The drugs aim to help your immune system fight the cancer more effectively.
This study tests a new pill combined with immunotherapy for people with advanced non-small cell lung cancer that has not been treated or has stopped responding to previous immunotherapy. The goal is to see if the combination is safe and helps shrink tumors.
This trial tests a three-drug combination (ipilimumab, nivolumab, and nogapendekin alfa inbakicept) as a first treatment for people with stage IV or recurrent non-small cell lung cancer. The goal is to see if this approach can help your immune system fight the cancer more effectively.
This trial tests a new combination of two drugs (Adibelimab and Famitinib) plus chemotherapy for people with advanced non-small cell lung cancer whose previous immunotherapy (PD-1 inhibitor) has stopped working. The goal is to see if this new combination can help control the cancer when the first treatment fails.
This trial tests a new combination of three medicines (Golidocitinib, Tislelizumab, and chemotherapy) as the first treatment for advanced non-small cell lung cancer (NSCLC). It is designed for people whose tumors have at least 1% PD-L1 and who have not had any previous treatment for advanced disease.
Hear when a new Lung Cancer, Non-Small Cell trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.